Home > Search Results: van de Velde, Helgi
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 2 records in 0.01 seconds.
Articles, 2 records found
Articles 2 records found  
1.
9 p, 982.6 KB Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis / Spicka, Ivan (Charles University and General Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Facon, Thierry (Lille University Hospital) ; Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital) ; Lim, Andrew (Austin and Repatriation Medical Center) ; Mikala, Gabor (South Pest Central Hospital) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Yağci, Münci (Gazi University) ; Cavo, Michele (Università di Bologna) ; Risse, Marie-Laure (Sanofi (França)) ; Asset, Gaëlle (Sanofi (França)) ; Macé, Sandrine (Sanofi (França)) ; Van de Velde, Helgi (Sanofi) ; Yong, Kwee (University College Hospital) ; Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512  
Detailed record - Creative Commons
2.
28 p, 10.5 MB Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model / Alé, Albert (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Bruna, Jordi (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Morell, Marta (Universitat Autònoma de Barcelona. Institut de Neurociències) ; van de Velde, Helgi (Janssen Research and Development) ; Monbaliu, Johan (Janssen Research and Development) ; Navarro, X. (Xavier) (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Udina i Bonet, Esther (Universitat Autònoma de Barcelona. Institut de Neurociències)
Bortezomib (BTZ), a proteasome inhibitor, is an effective anti-neoplastic drug used in the treatment of multiple myeloma and mantle cell lymphoma. However, it can induce a reversible peripheral neuropathy that may lead to treatment discontinuation. [...]
2014 - 10.1016/j.expneurol.2013.12.020
Experimental Neurology, Vol. 253 (march 2014) , p. 165-173  
Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with